Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axonics, Inc. stock logo
AXNX
Axonics
$70.98
$70.61
$67.49
$71.05
$3.63B0.82429,979 shsN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.38
-1.1%
$1.95
$1.30
$12.33
$50.06M1.31807,000 shs1.02 million shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.64
-0.5%
$3.07
$2.50
$9.37
$106.29M0.45305,012 shs75,171 shs
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
$27.49
$27.31
$6.08
$27.51
$1.12B1.531.20 million shsN/A
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axonics, Inc. stock logo
AXNX
Axonics
0.00%0.00%0.00%0.00%+4.81%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%0.00%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-4.14%-3.14%-38.22%-13.66%-85.02%
Pulmonx Corporation stock logo
LUNG
Pulmonx
-2.93%-4.50%-22.06%-49.52%-58.27%
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
0.00%0.00%0.00%0.00%+1.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.91 of 5 stars
3.31.00.04.42.90.01.3
Pulmonx Corporation stock logo
LUNG
Pulmonx
3.1897 of 5 stars
3.33.00.00.02.53.30.6
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
0.5722 of 5 stars
1.00.00.04.30.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axonics, Inc. stock logo
AXNX
Axonics
2.00
HoldN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00
N/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$8.80540.00% Upside
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.63
Moderate Buy$11.53336.88% Upside
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
2.00
Hold$27.500.04% Upside

Current Analyst Ratings Breakdown

Latest SILK, LUNG, AXNX, CSII, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$5.00
5/22/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axonics, Inc. stock logo
AXNX
Axonics
$366.38M9.90$0.13 per share561.96$12.59 per share5.64
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$283.10K178.12N/AN/A$1.90 per share0.72
Pulmonx Corporation stock logo
LUNG
Pulmonx
$83.79M1.27N/AN/A$2.17 per share1.22
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
$177.13M6.31N/AN/A$3.88 per share7.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axonics, Inc. stock logo
AXNX
Axonics
-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$3.19N/AN/AN/AN/A-136.93%-89.99%8/6/2025 (Estimated)
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
-$55.74M-$1.37N/AN/AN/A-29.53%-37.30%-21.57%N/A

Latest SILK, LUNG, AXNX, CSII, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.40N/AN/AN/A$23.46 millionN/A
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
5/7/2025Q1 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axonics, Inc. stock logo
AXNX
Axonics
N/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axonics, Inc. stock logo
AXNX
Axonics
N/A
8.16
6.40
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
2.63
2.63
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.38
4.97
4.29
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
0.49
7.63
6.69

Institutional Ownership

CompanyInstitutional Ownership
Axonics, Inc. stock logo
AXNX
Axonics
99.48%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
N/A

Insider Ownership

CompanyInsider Ownership
Axonics, Inc. stock logo
AXNX
Axonics
1.85%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Pulmonx Corporation stock logo
LUNG
Pulmonx
6.80%
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axonics, Inc. stock logo
AXNX
Axonics
61051.11 million50.16 millionOptionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million35.83 millionOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25040.26 million37.52 millionOptionable
Silk Road Medical, Inc stock logo
SILK
Silk Road Medical
41040.63 million37.91 millionOptionable

Recent News About These Companies

Three Andritz spunlace lines for Alear Silk Road
Xinjiang a front-runner in BRI medical cooperation
Trump pardons founder of Silk Road website
Trump Pardons Creator of Silk Road Drug Marketplace
Chinese, Pakistani firms sign $250m MoUs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Axonics stock logo

Axonics NASDAQ:AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Cardiovascular Systems stock logo

Cardiovascular Systems NASDAQ:CSII

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.38 -0.02 (-1.08%)
As of 12:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$2.64 -0.01 (-0.45%)
As of 12:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Silk Road Medical stock logo

Silk Road Medical NASDAQ:SILK

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.